Melane Sampson, Author at BioTuesdays

Developments

BiomX doses first patient in Phase 2b trial of BX004 in CF

BiomX (NYSE: PHGE) has announced the initiation of patient dosing in its Phase 2b trial evaluating BX004 for the treatment of cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas...

July 15, 2025

Feature

EsoBiotec unlocking new possibilities for oncology and autoimmune disease by empowering cells in vivo

Closely held EsoBiotec is transforming cell therapy by engineering immune cells directly within a patient’s body, enabling the immune system to attack disease—potentially delivering cell therapy to patients in minutes...

July 15, 2025

Developments

Firefly’s FDA-cleared BNA platform underpins groundbreaking precision neuroscience study with Heidelberg University

Firefly Neuroscience (NASDAQ: AIFF) has announced its continued collaboration with Prof. Christian Schaaf, MD, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Human Genetics...

July 14, 2025

Developments

Oncogene publishes remission for testicular cancer patient treated with MiNK’s iNKT cell therapy

MiNK Therapeutics (NASDAQ: INKT) has highlighted a publication in the peer-reviewed journal Oncogene describing a complete and durable remission in a patient with metastatic, treatment refractory testicular cancer...

July 11, 2025

Executive Moves

Quince appoints Dr. Hassan Abolhassani to SAB

Quince Therapeutics (NASDAQ: QNCX) has announced the appointment of leading immunologist, Hassan Abolhassani, MD, PhD, to its scientific advisory board (SAB). Dr. Abolhassani currently serves as assistant professor of...

July 11, 2025

Developments

China’s NMPA approves Ascentage’s lisaftoclax for CLL/SLL

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) has announced that China’s National Medical Products Administration (NMPA) has approved its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) for the...

July 10, 2025

Developments

PharmaJet enters MOU for needle-free vaccine delivery in Egypt

Closely held PharmaJet has announced the signing of a Memorandum of Understanding (MOU) with the Egyptian Unified Procurement Authority (UPA) and closely held EVA Pharma. The agreement aims to explore the integration of...

July 10, 2025

Executive Moves

New CFO and SVP join Ascentage

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) has announced the appointment of Veet Misra, PhD, as chief financial officer (CFO), and Eric Huang as senior vice president (SVP) of global corporate development and...

July 8, 2025

Executive Moves

Jeff Ervin joins Allarity as CFO

Allarity Therapeutics (NASDAQ: ALLR) has announced the appointment of Jeff Ervin as chief financial officer (CFO), succeeding Alexander Epshinsky, who will remain involved during the transition period. Mr. Ervin brings...

July 7, 2025

Developments

Cogent reports positive topline results from SUMMIT trial of bezuclastinib in NonAdvSM

Cogent Biosciences (NASDAQ: COGT) has announced positive topline results from the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM), achieving statistical significance across...

July 7, 2025

Author - Melane Sampson

BiomX doses first patient in Phase 2b trial of BX004 in CF

EsoBiotec unlocking new possibilities for oncology and autoimmune disease by empowering cells in vivo

Firefly’s FDA-cleared BNA platform underpins groundbreaking precision neuroscience study with Heidelberg University

Oncogene publishes remission for testicular cancer patient treated with MiNK’s iNKT cell therapy

Quince appoints Dr. Hassan Abolhassani to SAB

China’s NMPA approves Ascentage’s lisaftoclax for CLL/SLL

PharmaJet enters MOU for needle-free vaccine delivery in Egypt

New CFO and SVP join Ascentage

Jeff Ervin joins Allarity as CFO

Cogent reports positive topline results from SUMMIT trial of bezuclastinib in NonAdvSM

Subscribe